U.S. markets closed

vTv Therapeutics Inc. (VTVT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4600-0.0300 (-1.20%)
At close: 4:00PM EDT
2.4600 0.00 (0.00%)
After hours: 07:53PM EDT

vTv Therapeutics Inc.

3980 Premier Drive
Suite 310
High Point, NC 27265
United States
336 841 0300
http://www.vtvtherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees25

Key Executives

NameTitlePayExercisedYear Born
Ms. Robin E. AbramsExec. Chairwoman of the Board420kN/A1964
Mr. Stephen L. HolcombePres & CEO684.65kN/A1957
Mr. Rudy C. Howard CPA, B.A., CPAExec. VP & CFO487.18kN/A1958
Dr. Carmen Valcarce Ph.D.Chief Scientific Officer & Exec. VPN/AN/AN/A
Mr. David M. Lambert IIISr. VP & Gen. CounselN/AN/AN/A
Dr. Aaron H. BursteinSr. VP of Clinical Devel.N/AN/AN/A
Dr. Robert C. AndrewsSr. VP of Chemistry, Pharmaceutical Devel. and QualityN/AN/AN/A
Dr. Samuel B. Rollins Ph.D., J.D.Sr. VP of Intellectual PropertyN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Corporate Governance

vTv Therapeutics Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.